Episode Details

Today's AI landscape reveals a stark contrast between open innovation and corporate consolidation. While Ant Group and Liquid AI push boundaries with open-source foundation models, Meta's aggressive data harvesting and Microsoft's inward cost-cutting signal a tightening grip on the frontier. Meanwhile, AI-driven drug discovery reaches a milestone that could reshape how we think about AI's real-world impact.